The oversight of clinical innovation in a medical marketplace

Wendy Lipworth; Miriam Wiersma; Narcyz Ghinea; Tereza Hendl; Ian Kerridge; Tamra Lysaght; Megan Munsie; Chris Rudge; Cameron Stewart; Catherine Waldby

doi:10.1017/9781108620024.036

The oversight of clinical innovation in a medical marketplace

Wendy Lipworth, Miriam Wiersma, Narcyz Ghinea, Tereza Hendl, Ian Kerridge, Tamra Lysaght, Megan Munsie, Chris Rudge, Cameron Stewart, Catherine Waldby

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

3 Citations (Scopus)

64 Downloads (Pure)

Abstract

Clinical innovation is ubiquitous in medical practice and is generally viewed as both necessary and desirable. While innovation has been the source of considerable benefit, many clinical innovations have failed to demonstrate evidence of clinical benefit and/or caused harm. Given uncertainly regarding the consequences of innovation, it is broadly accepted that it needs some form of oversight. But there is also pushback against what is perceived to be obstruction of access to innovative interventions. In this chapter, we argue that this pushback is misguided and dangerous – particularly because of the myriad competing and conflicting interests that drive and shape clinical innovation.

Original language	English
Title of host publication	The Cambridge handbook of health research regulation
Editors	Graeme Laurie, Edward Dove, Agomoni Ganguli-Mitra, Catriona McMillan, Emily Postan, Nayha Sethi, Annie Sorbie
Place of Publication	Cambridge, UK
Publisher	Cambridge University Press (CUP)
Chapter	29
Pages	287-295
Number of pages	9
ISBN (Electronic)	9781108620024
ISBN (Print)	9781108475976
DOIs	https://doi.org/10.1017/9781108620024.036
Publication status	Published - Jun 2021
Externally published	Yes

Bibliographical note

Copyright the Publisher 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

autologous stem cells
biomedical innovation
clinical innovation
conflict of interest
integrity

Access to Document

10.1017/9781108620024.036

Publisher version (open access)Final published version, 113 KBLicence: CC BY

Cite this

Lipworth, W., Wiersma, M., Ghinea, N., Hendl, T., Kerridge, I., Lysaght, T., Munsie, M., Rudge, C., Stewart, C., & Waldby, C. (2021). The oversight of clinical innovation in a medical marketplace. In G. Laurie, E. Dove, A. Ganguli-Mitra, C. McMillan, E. Postan, N. Sethi, & A. Sorbie (Eds.), The Cambridge handbook of health research regulation (pp. 287-295). Cambridge University Press (CUP). https://doi.org/10.1017/9781108620024.036

Lipworth, Wendy ; Wiersma, Miriam ; Ghinea, Narcyz et al. / The oversight of clinical innovation in a medical marketplace. The Cambridge handbook of health research regulation. editor / Graeme Laurie ; Edward Dove ; Agomoni Ganguli-Mitra ; Catriona McMillan ; Emily Postan ; Nayha Sethi ; Annie Sorbie. Cambridge, UK : Cambridge University Press (CUP), 2021. pp. 287-295

@inbook{422d7493656747fba89af4b9e4514718,

title = "The oversight of clinical innovation in a medical marketplace",

abstract = "Clinical innovation is ubiquitous in medical practice and is generally viewed as both necessary and desirable. While innovation has been the source of considerable benefit, many clinical innovations have failed to demonstrate evidence of clinical benefit and/or caused harm. Given uncertainly regarding the consequences of innovation, it is broadly accepted that it needs some form of oversight. But there is also pushback against what is perceived to be obstruction of access to innovative interventions. In this chapter, we argue that this pushback is misguided and dangerous – particularly because of the myriad competing and conflicting interests that drive and shape clinical innovation.",

keywords = "autologous stem cells, biomedical innovation, clinical innovation, conflict of interest, integrity",

author = "Wendy Lipworth and Miriam Wiersma and Narcyz Ghinea and Tereza Hendl and Ian Kerridge and Tamra Lysaght and Megan Munsie and Chris Rudge and Cameron Stewart and Catherine Waldby",

note = "Copyright the Publisher 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2021",

month = jun,

doi = "10.1017/9781108620024.036",

language = "English",

isbn = "9781108475976",

pages = "287--295",

editor = "Graeme Laurie and Edward Dove and Agomoni Ganguli-Mitra and Catriona McMillan and Emily Postan and Nayha Sethi and Annie Sorbie",

booktitle = "The Cambridge handbook of health research regulation",

publisher = "Cambridge University Press (CUP)",

address = "United Kingdom",

}

Lipworth, W, Wiersma, M, Ghinea, N, Hendl, T, Kerridge, I, Lysaght, T, Munsie, M, Rudge, C, Stewart, C & Waldby, C 2021, The oversight of clinical innovation in a medical marketplace. in G Laurie, E Dove, A Ganguli-Mitra, C McMillan, E Postan, N Sethi & A Sorbie (eds), The Cambridge handbook of health research regulation. Cambridge University Press (CUP), Cambridge, UK, pp. 287-295. https://doi.org/10.1017/9781108620024.036

The oversight of clinical innovation in a medical marketplace. / Lipworth, Wendy; Wiersma, Miriam; Ghinea, Narcyz et al.
The Cambridge handbook of health research regulation. ed. / Graeme Laurie; Edward Dove; Agomoni Ganguli-Mitra; Catriona McMillan; Emily Postan; Nayha Sethi; Annie Sorbie. Cambridge, UK: Cambridge University Press (CUP), 2021. p. 287-295.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - The oversight of clinical innovation in a medical marketplace

AU - Lipworth, Wendy

AU - Wiersma, Miriam

AU - Ghinea, Narcyz

AU - Hendl, Tereza

AU - Kerridge, Ian

AU - Lysaght, Tamra

AU - Munsie, Megan

AU - Rudge, Chris

AU - Stewart, Cameron

AU - Waldby, Catherine

N1 - Copyright the Publisher 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2021/6

Y1 - 2021/6

N2 - Clinical innovation is ubiquitous in medical practice and is generally viewed as both necessary and desirable. While innovation has been the source of considerable benefit, many clinical innovations have failed to demonstrate evidence of clinical benefit and/or caused harm. Given uncertainly regarding the consequences of innovation, it is broadly accepted that it needs some form of oversight. But there is also pushback against what is perceived to be obstruction of access to innovative interventions. In this chapter, we argue that this pushback is misguided and dangerous – particularly because of the myriad competing and conflicting interests that drive and shape clinical innovation.

AB - Clinical innovation is ubiquitous in medical practice and is generally viewed as both necessary and desirable. While innovation has been the source of considerable benefit, many clinical innovations have failed to demonstrate evidence of clinical benefit and/or caused harm. Given uncertainly regarding the consequences of innovation, it is broadly accepted that it needs some form of oversight. But there is also pushback against what is perceived to be obstruction of access to innovative interventions. In this chapter, we argue that this pushback is misguided and dangerous – particularly because of the myriad competing and conflicting interests that drive and shape clinical innovation.

KW - autologous stem cells

KW - biomedical innovation

KW - clinical innovation

KW - conflict of interest

KW - integrity

UR - http://www.scopus.com/inward/record.url?scp=85146298597&partnerID=8YFLogxK

U2 - 10.1017/9781108620024.036

DO - 10.1017/9781108620024.036

M3 - Chapter

SN - 9781108475976

SP - 287

EP - 295

BT - The Cambridge handbook of health research regulation

A2 - Laurie, Graeme

A2 - Dove, Edward

A2 - Ganguli-Mitra, Agomoni

A2 - McMillan, Catriona

A2 - Postan, Emily

A2 - Sethi, Nayha

A2 - Sorbie, Annie

PB - Cambridge University Press (CUP)

CY - Cambridge, UK

ER -

Lipworth W, Wiersma M, Ghinea N, Hendl T, Kerridge I, Lysaght T et al. The oversight of clinical innovation in a medical marketplace. In Laurie G, Dove E, Ganguli-Mitra A, McMillan C, Postan E, Sethi N, Sorbie A, editors, The Cambridge handbook of health research regulation. Cambridge, UK: Cambridge University Press (CUP). 2021. p. 287-295 doi: 10.1017/9781108620024.036

The oversight of clinical innovation in a medical marketplace

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this